SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as a report surfaced regarding security flaws in a battlefield communication system, triggering a sharp sell-off despite the company's rebuttal and claims that the issues were resolved. The community is debating the severity and validity of the report, with some viewing it as a buying opportunity while others express concerns about the company's valuation. Discussions also involve the potential impact on government contracts and the trustworthiness of news sources.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions around Novo Nordisk's potential entry into the telehealth space with an obesity pill, which could impact HIMS' market share, while others are pointing out that weightloss is only a small part of the business. The community is debating whether this news presents a buying opportunity or signals a concerning shift in the competitive landscape, especially since some are looking at the COO exit as a negative catalyst. Some traders are noting technical levels and expressing frustration with the stock's volatile price action and seeming sensitivity to news.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid high trading volume and anticipation surrounding potential catalysts, including upcoming airshows and FAA certification progress. The community is actively discussing the possibility of a short squeeze, as well as potential partnerships, with some drawing attention to Tesla's presence in a recent promotional video. Discussions also involve comparisons to sector peer Joby Aviation, with some traders anticipating $ACHR closing the market cap gap.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics is trending due to significant volume and positive price action, with the community anticipating a potential breakout. Discussions revolve around upcoming catalysts like a robotics conference and potential partnerships, fueling speculation of a continued uptrend. Some traders highlight the stock's increasing institutional interest and potential for a short squeeze, while others express caution due to the recent surge.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate its AI spending and monetization strategies, highlighted by a recent report on AI chatbots exploring ad revenue. Community chatter reflects concerns about its recent price action, with some viewing it as a buying opportunity while others express bearish sentiment. Broader discussions include Meta's competition in the AI and AR spaces, particularly around its smart glasses.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge, fueled by speculation around the quantum computing sector, despite some cautioning about inflated valuations. Community chatter highlights significant option activity and debates whether the stock's rise is justified by its fundamentals or driven by hype and potential short squeezes. Some traders are closely watching ULTY's position in RGTI to gauge future price movement.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai Inc. ($AI) is trending amid speculation around potential M&A activity, particularly buyout rumors involving companies like Apple. The surge in call option volume and overall bullish sentiment, especially concerning the company's AI technology and federal contracts, is driving community discussion. Despite recent executive stock sales and mixed sentiment regarding past performance, the focus remains on C3.ai's potential in the growing AI sector.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as the community discusses its recent price movement, increased volume, and potential catalysts, including a possible buyout. Community members are analyzing chart patterns and speculating on a buyout, with some pointing to the company's new license structure and partnership with Recordati as potential drivers. Others discuss the possibility of a sector-related surge and the potential for future profitability.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

CLNN is trending as community members discuss the potential for accelerated approval of its ALS treatment following positive commentary from the FDA. Conversations revolve around the company's cash flow, potential offerings, and the possibility of a data leak driving the recent price movement. Some investors express excitement and relief, while others remain cautious due to past experiences and the need for further positive developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending due to positive developments, including a new U.S. patent approval and institutional support, sparking discussions of a potential weekend hold. The community is weighing the possibility of a short squeeze and a potential offering, while noting the stock's resilience around key support levels. Some analysts see a promising future for the company based on a new psychiatric biomarker strategy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? 

BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.

Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?

Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.

BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?

Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.

Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?

Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.

Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why

Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Black Diamond Therapeutics (BDTX) This Year?

Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Shares of Black Diamond Therapeutics, Inc. (BDTX) jumped around 21% as of Wednesday noon after the company announced it had entered into a <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/servier-and-black-diamond-therapeutics-announce-global-licensing">licensing agreement</a> with Servier, a French pharmaceutical group.As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.Under the agreement, Black Diamond will receive an upfront payment of $70 million and can receive up to $710 million in future payments, including development and commercial sales milestone payments and tiered royalties based on net sales.The company said earlier this month that its cash, cash equivalents, and investment of $98.6 million as of the end of 2024 would be sufficient to fund operations and capital expenditure requirements into the last quarter of 2026.On Stocktwits, retail sentiment around Black Diamond’s stock rose to a year-high, jumping higher within the ‘extremely bullish’ territory (100/100). Meanwhile, message volume surged to ‘extremely high’ levels from ‘high’ in the past 24 hours.<figure class="image"><img style="aspect-ratio:810/187;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_140848_png_e163bd613a.webp" alt="Black Diamond Therapeutics' Sentiment Meter and Message Volume as of 2:00 p.m. ET on March 19, 2025 | Source: Stocktwits" width="810" height="187"><figcaption>Black Diamond Therapeutics' Sentiment Meter and Message Volume as of 2:00 p.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the shares rising as high as $6 from its current value of over $2.&nbsp;<stembedurl>https://stocktwits.com/DaSqueeza/message/608568813</stembedurl>Another opined that a “strong reversal” is coming for the stock.<stembedurl>https://stocktwits.com/alecsalaur198/message/608560099</stembedurl><a href="https://stocktwits.com/symbol/BDTX">Black Diamond shares</a> are down by over 50% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer. 

Equity

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With a 36% objective response rate and encouraging durability, BDTX-1535 shows...

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Black Diamond Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$3.89
Prev Close	$3.73
Open	$3.75
Dividend Yield	0.00%
50-Day Moving Average	$2.98
Beta	1.68
Avg. Volume	1.03M
PE Ratio	15.75

52-Week High	$3.87
52-Week Low	$1.20
Market Capitalization	$212.37M
EPS (Annual)	-$1.27
Price to Book	1.60
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BDTX
Black Diamond Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BDTX News

BDTX Black Diamond Therapeutics Inc